Drugs / gandotinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01520220 | Jun 2012 → Jun 2015 | acquired polycythemia vera, essential thrombocythemia, myelofibrosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01134120 | Apr 2010 → Apr 2014 | acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01594723 | May 2012 → Mar 2015 overdue | hematopoietic and lymphoid system neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2012-07-07 | Celon Pharma SA | Results Jesteśmy na EACR w Barcelonie celonpharma.com ↗
Differential gene transcription response to the treatment with JAK2 inhibitors – Ruxolitinib, SAR302503 and LY2784544 . |
| 2011-12-12 | Eli Lilly and Company | Results Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting lilly.com ↗ |
| 2011-04-04 | Eli Lilly and Company | Results Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer lilly.com ↗
Research presented at AACR's New Small Molecule Therapeutics mini-symposium suggested that the investigational compound LY2784544, a small-molecule JAK2 inhibitor, blocks a specific, difficult-to-isolate, signaling pathway that can lead to the development of cancer cells. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-07-07 | Celon Pharma SA | Jesteśmy na EACR w Barcelonie celonpharma.com ↗ |
| 2011-12-12 | Eli Lilly and Company | Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting lilly.com ↗ |
| 2011-04-04 | Eli Lilly and Company | Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer lilly.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gandotinib | “A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.” PMID 28934680 ↗ Aug 2017 |
| Known as | GANDOTINIB (LY2784544) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107823 ↗ |
| Known as | LY2784544 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01520220 ↗ |
| Action | Inhibit | “a potent inhibitor of JAK2 activity” PMID 28934680 ↗ Aug 2017 |
| Modality | Small molecule | — CHEMBL2107823 ↗ |
| Route | Oral | “The study drug will be taken by mouth daily while the patient is on study.” NCT01134120 ↗ |
| Target | JAK2 | “a potent inhibitor of JAK2 activity” PMID 28934680 ↗ Aug 2017 |